UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 264

Sortiert nach

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Nature reviews. Clinical oncology, 2019-06, Vol.16 (6), p.341-355

2019

Volltextzugriff (PDF)

Molecular Pathways: ROS1 Fusion Proteins in Cancer

Clinical cancer research, 2013-08, Vol.19 (15), p.4040-4045

2013

Volltextzugriff (PDF)

Acquired Resistance Is Oncogene and Drug Agnostic

Cancer cell, 2019-10, Vol.36 (4), p.347-349

Doebele, Robert C.

2019

Volltextzugriff (PDF)

TRKing down an old oncogene in a new era of targeted therapy

Cancer discovery, 2015-01, Vol.5 (1), p.25-34

2015

Volltextzugriff (PDF)

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Nature medicine, 2016-05, Vol.22 (5), p.472-478

2016

Volltextzugriff (PDF)

Treating ALK-positive lung cancer--early successes and future challenges

Nature reviews. Clinical oncology, 2012-05, Vol.9 (5), p.268-277

2012

Volltextzugriff (PDF)

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

Nature medicine, 2018-05, Vol.24 (5), p.638-646

2018

Volltextzugriff (PDF)

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The lancet oncology, 2021-07, Vol.22 (7), p.959-969

2021

Volltextzugriff (PDF)

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

International journal of radiation oncology, biology, physics, 2014-03, Vol.88 (4), p.892-898

2014

Volltextzugriff (PDF)

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1474-1482

2018

Volltextzugriff (PDF)

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

PloS one, 2013-12, Vol.8 (12), p.e82236

2013

Volltextzugriff (PDF)

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Journal of clinical oncology, 2019-06, Vol.37 (18), p.1558-1565

2019

Volltextzugriff (PDF)

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-08, Vol.34 (24), p.2814-2819

2016

Volltextzugriff (PDF)

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

PloS one, 2010-11, Vol.5 (11), p.e14117

2010

Volltextzugriff (PDF)

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1807-1814

2012

Volltextzugriff (PDF)

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4570-4579

2012

Volltextzugriff (PDF)

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2758-2770

2018

Volltextzugriff (PDF)

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical cancer research, 2021-03, Vol.27 (5), p.1463-1475

2021

Volltextzugriff (PDF)

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

Seminars in oncology, 2014-02, Vol.41 (1), p.110-125

2014

Volltextzugriff (PDF)

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Clinical cancer research, 2019-10, Vol.25 (19), p.5832-5842

2019

Volltextzugriff (PDF)

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Clinical cancer research, 2010-11, Vol.16 (22), p.5581-5590

2010

Volltextzugriff (PDF)

1 – 25 von 264

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(249)

Publikationsform

Sprache

Englisch
(264)
Japanisch
(52)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(124)
Life Sciences & Biomedicine
(122)
Humans
(111)
Oncology
(99)
Lung Neoplasms - Drug Therapy
(55)
Lung Neoplasms - Genetics
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(48)
Male
(47)
Female
(46)
Carcinoma, Non-Small-Cell Lung - Genetics
(44)
Middle Aged
(41)
Lung Neoplasms - Pathology
(38)
Lung Cancer
(37)
Mutation
(36)
Carcinoma, Non-Small-Cell Lung - Pathology
(32)
Aged
(30)
Respiratory System
(29)
Adult
(28)
Protein Kinase Inhibitors - Therapeutic Use
(28)
Tumors
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Molecular Pathways: ROS1 Fusion Proteins in Cancer

Acquired Resistance Is Oncogene and Drug Agnostic

TRKing down an old oncogene in a new era of targeted therapy

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Treating ALK-positive lung cancer--early successes and future challenges

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Aktive Filter

Suchergebnisse filtern